Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 12/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365962 | 0.89 | HPGDS (0.41) | RIPK1HPGDSMAP4K4HDAC3HDAC4 | |
| SCHEMBL1365108 | 0.87 | MAP4K4 (0.50) | HPGDSMAP4K4HDAC3HDAC4HDAC7 | |
| SCHEMBL1364924 | 0.86 | HDAC3 (0.46) | HPGDSMAP4K4HDAC3HDAC4HDAC7 | |
| SCHEMBL1364922 | 0.86 | HDAC3 (0.46) | HPGDSMAP4K4HDAC3HDAC4HDAC7 | |
| SCHEMBL4085534 | 0.86 | HDAC3 (0.46) | HPGDSMAP4K4HDAC3HDAC4HDAC7 | |
| SCHEMBL1364921 | 0.86 | HDAC3 (0.46) | HPGDSMAP4K4HDAC3HDAC4HDAC7 | |
| SCHEMBL1366021 | 0.81 | DRD2 (0.52) | USP30HPGDSMAP4K4 | |
| SCHEMBL1542844 | 0.78 | HPGDS (0.55) | USP30HPGDSMAP4K4 | |
| SCHEMBL1366297 | 0.76 | MAP4K4 (0.46) | HPGDSMAP4K4HDAC3HDAC6 | |
| SCHEMBL1366300 | 0.76 | MAP4K4 (0.46) | HPGDSMAP4K4HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | RIPK1 4627/4885USP30 4116/4885HPGDS 99/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | RIPK1 4627/4885USP30 4116/4885HPGDS 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.